trimethoprim has been researched along with sori 8895 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gangjee, A; Kisliuk, RL; Queener, SF; Vasudevan, A | 1 |
| Borotz, SE; Carter, RL; Hosmer, CA; Johnson, CA; Krauth, CA; Pfefferkorn, ER; Piper, JR; Queener, SF | 1 |
| Gangjee, A; Queener, SF; Vasudevan, A | 1 |
3 other study(ies) available for trimethoprim and sori 8895
| Article | Year |
|---|---|
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Pneumocystis; Pyrimidines; Rats; Toxoplasma | 1995 |
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
Topics: Animals; Anti-Infective Agents; Folic Acid Antagonists; Opportunistic Infections; Pneumocystis; Pneumonia, Pneumocystis; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Toxoplasmosis; Trimetrexate | 1996 |
Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
Topics: AIDS-Related Opportunistic Infections; Animals; Folic Acid Antagonists; Humans; Liver; Mice; Pneumocystis; Pyrimidines; Rats; Tetrahydrofolate Dehydrogenase; Toxoplasma; Trimetrexate | 1997 |